Clinical trial results in Alzheimer’s Disease (AD) reported over the past few weeks have been disappointing to both patients and the academic community. The failure of both bapineuzumab (Pfizer/Johnson & Johnson) and solanezumab (Eli Lilly) to improve cognitive function has shown the difficulties inherent in trying to develop drugs to [...]